BSE filing, BSE: 544445. Summary written from the filing by ALFA Finder's alert engine.
Asston Pharmaceuticals Ltd: key numbers
- Share price
- ₹146.25
- Market cap
- ₹124.5 Cr
- Revenue (annual)
- ₹25.47 Cr
- Net profit (annual)
- ₹3.87 Cr
- P/E (TTM)
- 32.2×Sector 46.1×
- Promoter holding
- 39.48%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Asston Pharmaceuticals Ltd
All →Asston Pharmaceuticals Other Announcement
Asston Pharmaceuticals Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026. It also disclosed a recent preferential allotment of 24.10 lakh equity shares.
Asston Pharmaceuticals Other Announcement
Asston Pharmaceuticals Limited announced a change in the company's registered office address within the same city, effective from 15th October 2026.
Asston Pharmaceuticals Capital Structure Change
The company submitted a revised shareholding pattern following the allotment of 24,10,431 equity shares through a preferential allotment dated September 5, 2026.
Asston Pharmaceuticals Board Meeting Date
Asston Pharmaceuticals Limited has scheduled a board meeting on 13 October 2026 to consider other business matters. The company's trading window remains closed until 17 October 2026.
Asston Pharmaceuticals Other Announcement
Asston Pharmaceuticals Limited has appointed M/s. Panchal S K & Associates as its Statutory Auditor for a five-year term. The appointment is effective from April 1, 2026.
- Execution
- 60 months
Asston Pharmaceuticals Annual General Meeting
Asston Pharmaceuticals Limited concluded its 7th Annual General Meeting on September 29, 2026. Shareholders considered resolutions including adoption of financial statements and director remuneration increases.
Other capital structure change announcements
All →Emkay Global Financial Services Capital Structure Change
Emkay Global will invest ₹30.00 Crore in cash in wholly owned subsidiary Emkay Capital. The related-party deal completes within 90 days.
- Value
- ₹30.00 Cr
- Execution
- Within 90 days
OnEMI Technology Solutions Capital Structure Change
OnEMI will invest ₹624.15 Crore in its wholly owned subsidiary Si Creva via rights subscription. Funds come from preferential issue proceeds, completing by December 2026.
- Value
- ₹624.1 Cr
- Execution
- By end of December 2026
Meesho Capital Structure Change
Meesho approved up to Rs.400 Crore capital infusion into its wholly owned subsidiary, Meesho Payments. Board also approved a new subsidiary and further Kirana Club investments.
- Value
- ₹400.0 Cr
Womancart Capital Structure Change
Womancart Limited submitted its draft letter of offer for a rights issue of up to Rs.1,200 lakhs to eligible shareholders. The issue is pending in-principle approval from NSE Emerge, with the price, ratio and dates still blank.
- Value
- ₹12.00 Cr
Hero MotoCorp Capital Structure Change
Hero MotoCorp's board approved up to ₹300 Crore additional investment in wholly-owned subsidiary HMCL Netherlands B.V., in tranches over two years. Quarterly results were also approved.
- Value
- ₹300.0 Cr
- Execution
- 2 years, in one or more tranches
Great Eastern Shipping Company Capital Structure Change
Great Eastern Shipping bought back 88,877 equity shares on 28 October 2026 at an average of Rs.1,529.71. Total shares bought back under the open-market buyback now stand at 38,48,494.
- Value
- ₹13.60 Cr